Freddy Tablet (Methylprednisolone)

Adult dosage

The initial dosage may vary from 4 mg to 48 mg per day as methylprednisolone, depending on the symptoms of the specific disease. In general, a low dose is sufficient for conditions that are not severe, but a high initial dose may be required in certain patients. The initial dose should be maintained or adjusted until a satisfactory response is obtained. The dosage must be determined individually according to the various diseases being treated and the patient's response. After an adequate response is achieved, an appropriate maintenance dose should be determined by reducing the initial dose at appropriate intervals until the minimum dose that maintains an adequate clinical response is reached. After long-term treatment, gradual dose reduction is recommended when discontinuing the drug. Treatment of acute exacerbations of multiple sclerosis is effective with prednisolone 200 mg daily for 1 week, followed by prednisolone 80 mg every other day for 1 month (methylprednisolone 4 mg is equivalent to prednisolone 5 mg). Alternate-day therapy is a regimen in which twice the daily dose is given on one morning every 2 days. A single morning dose results in considerably less adrenal suppression than taking prednisolone (10 mg) in 4 divided doses every 6 hours. The initial suppressive dose should be continued until a satisfactory clinical response is obtained, usually for 4 to 10 days for many allergic and collagen diseases. Convert to ADT and gradually reduce the amount of corticosteroid given every other day. As disease progression is brought under control, reduce the daily corticosteroid dose to the minimum effective dose as soon as possible, and then change to an alternate-day schedule. Regular attempts to change the regimen are recommended. If this is difficult, administering 3 times or even 4 times the daily dose every other day is preferable to simply doubling the daily dose. Once the patient is controlled again, attempt to reduce this dose to the minimum. If an acute exacerbation occurs during disease progression, it may be necessary to return to a fully suppressive corticosteroid dose divided throughout the day to achieve control. Once control is achieved, the established alternate-day regimen may be tried again.

This medication should not be used in patients with a history of allergy or hypersensitivity to this drug or any of its components. It should not be administered to patients with infections that could be aggravated and without appropriate antimicrobials, or those with systemic fungal infections. Patients with viral infections such as herpes simplex, herpes zoster, or chickenpox should also not use this medication. This medication should not be used in patients receiving live or attenuated live vaccines, especially in immunocompromised states where vaccination may be risky. As this medication contains lactose, it should not be used in patients with genetic metabolic conditions such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. Patients with certain diseases such as glaucoma, tuberculosis, keratitis, cataracts, electrolyte abnormalities, hypertension, thrombosis, and those who have recently undergone bowel anastomosis should use this medication with caution and require careful monitoring by a physician, as symptoms may worsen. This medication can suppress immune function, increasing the risk of infections, so it should be used with heightened caution in patients with infections, diabetes, osteoporosis, renal failure, heart failure, hypothyroidism, fatty liver disease, myasthenia gravis, and elderly individuals. Long-term use may lead to adrenal insufficiency, osteoporosis, hypertension, diabetes, and possibly other side effects; therefore, it is essential to use the minimal effective dose and duration, and taper off gradually rather than suddenly stopping. While using this medication, patients should take care to avoid exposure to infections such as chickenpox or measles, and immediately consult healthcare professionals if exposure occurs or an infection is suspected. This medication may interact with multiple drugs; thus, it is essential to consult a physician or pharmacist if other medications are being taken. During pregnancy, it should only be given if necessary, as it may affect the fetus, and during breastfeeding, it is advised to stop breastfeeding as this medication can be excreted in breast milk. In pediatric patients, since there is a risk of side effects such as growth delay, the minimum dose should be used, and growth should be closely monitored. Elderly patients have a higher risk of side effects such as infections, diabetes, osteoporosis, and glaucoma; hence, careful monitoring is required during treatment. During treatment with this medication, various adverse reactions such as edema, muscle weakness, gastrointestinal symptoms, skin changes, and psychological or neurological symptoms may occur, and any such symptoms should be immediately reported to healthcare professionals.

Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalosis, congestive heart failure, hypertension, myasthenia, aseptic necrosis of the femoral and humeral heads, steroid myopathy, muscle wasting, pathological fractures of the pelvis, osteoporosis, spinal compression fractures, arthralgia, tendon rupture, increased ALT, increased AST, increased ALP, nausea, dry mouth, vomiting, abdominal pain, appetite loss, appetite increase, peptic ulcer, abdominal distension, pancreatitis, esophagitis, diarrhea, delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae, ecchymosis, suppression of skin reactions, purpura, acne, hirsutism, hair loss, pigmentation, increased intracranial pressure, papilledema, convulsions, dizziness, headache, insomnia, euphoria, depression, Cushing's syndrome, menstrual irregularities, growth suppression in children, latent diabetes symptoms, secondary adrenal insufficiency, pituitary unresponsiveness, decreased glucose tolerance, increased requirements for insulin or oral hypoglycemic agents, suppression of adrenocorticotropic hormone secretion, increased intraocular pressure, glaucoma, posterior subcapsular cataract, secondary eye infections due to fungi or viruses, central serous chorioretinopathy, retinal disorders, exophthalmos, negative nitrogen balance due to protein catabolism, immune system disorders, allergic reactions, shock, urticaria, anaphylactic reactions, hypersensitivity reactions

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to keep the storage temperature between 1 and 30 degrees Celsius to maintain the efficacy of the medication over time.

Appearance

White round tablet

Package unit

30 tablets/bottle, 500 tablets/bottle